Laboratoire des Substances Bioactives, Centre de Biotechnologie de Borj-Cedria (CBBC), BP-901, 2050, Hammam-Lif, Tunisia.
Faculté de pharmacie, MMS EA 2160, Université de Nantes, 44000, Nantes, France.
World J Microbiol Biotechnol. 2018 Jun 19;34(7):98. doi: 10.1007/s11274-018-2482-z.
A Trichoderma orientale strain LSBA1 was isolated from the Mediterranean marine sponge Cymbaxinella damicornis. The crude extract of T. orientale mycelium showed inhibitory activity against growth of Gram-positive and Gram-negative bacteria as well as clinical isolates of Candida albicans. Purification of the anti-Candida component was performed using a combination of open silica gel-60 column and reverse phase high performance liquid chromatography. The active compound called hyporientalin A has been identified as a peptaibol analogue of longibrachin-A-II using mass spectrometry. It exhibited fungicidal activity against clinical isolates of C. albicans with minimal inhibitory concentrations (MICs) ranging from 2.49 to 19.66 µM, comparable to that of the antifungal agent amphotericin B. Our data support the use of hyporientalin A as a promising new and efficient antifungal drug in the treatment of candidiasis while controlling toxicity.
从地中海海绵 C. damicornis 中分离到一株东方拟青霉 LSBA1。东方拟青霉菌丝体的粗提物对革兰氏阳性和革兰氏阴性细菌以及临床分离的白色念珠菌均表现出抑制活性。使用开放硅胶 60 柱和反相高效液相色谱的组合对抗真菌成分进行了纯化。该活性化合物被命名为hyporientalin A，它是一种具有长丝菌素-A-II 结构的肽类抗生素，通过质谱鉴定。它对临床分离的白色念珠菌表现出杀菌活性，最小抑菌浓度 (MIC) 范围为 2.49 至 19.66 µM，与抗真菌药物两性霉素 B 相当。我们的数据支持使用 hyporientalin A 作为一种有前途的新型有效抗真菌药物，用于治疗念珠菌病，同时控制毒性。
